Rick Schnellman

Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC.

Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC.

Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky.

Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC.

Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC.

Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky.

Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC.

Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC.